Celldex Sets it Straight at ASCO

After Celldex’s flubbed pre-ASCO abstract release led investor to question interim Phase II data for its cancer vaccine CDX-110 (PF-04948568), also with the generic name Rindopepimut, they made sure to.

Vivus Has a Hit in Qnexa

Obesity has a high prevalence in the US and is now frequently cited as being a national health issue. It is on the rise in almost every industrialized and some.

Investment Opportunities in Women’s Health

The next several months will be an exciting time for the women’s health space, with several important events that may represent an opportunity for investors. Most notably, Pfizer (PFE) has.

Alexion Pharmaceuticals- Poster Child for Ultra-orphan Treatments

Alexion got some good news today, receiving earlier than expected approval for its drug, Soliris (eculizumab), for the treatment of PNH in Japan- the world’s second largest pharmaceuticals market. Having.

Roche- Leading the Way in Personalized Medicine

(Featured in TheBigRedBiotechBlog) This Swiss pharma is the third largest pharmaceutical company both by revenue and market cap. It is one of the fastest growing companies in its peer group,.

Next Generation Antibody Technologies- Seattle Genetics Leads the Way

Next Generation Antibody Technologies- Seattle Genetics Leads the Way Monoclonal Antibody Technology has revolutionized medicine. Since 1986, more than 20 Antibody drugs have been approved, with sales of $26 Billion.

Incyte Pharmaceuticals: JAK it Up

Incyte Pharmaceuticals: JAK it Up Incyte Pharmaceuticals has one of the most promising pipelines in the small to mid-cap space. It has two very promising compounds in development, INCB18424 for.

Biotech’s One-Trick Pony

The One-Trick Pony We’ve heard this many times- never bet on that one-trick pony. Risky bet. You’ll lose your shirt. So what does this one-trick pony thing look like? What.

The Promise Behind Celldex- ASCO 2010

The Promise Behind Celldex Celldex shares climbed steadily in the months leading up to the release of its ASCO abstracts, rising from $4.71 at the start of the year and.

Bionovo: novel approach, challenges ahead, but poised to move higher

The Women’s Health Initiative (WHI), a study that demonstrated several lethal side-effects of hormone replacement therapy (HRT), has left many pharmaceutical companies scrambling to advance alternative therapies to meet the.

Serada Half Price Sale: DepoMed’s Stock Price Poised to Climb

Several weeks ago, DepoMed (NASDAQ:DEPO), a specialty pharmaceutical company, announced positive phase 3 trial results for the treatment of Post Herpetic Neuralgia (‘PHN’) with DM1796. But DepoMed’s news of success.

Weight loss, as easy as taking a Qnexa pill

Vivus Pharmaceuticals shocked the health-care industry earlier this year when it announced positive phase III results for it’s new obesity miracle drug. The drug, dubbed Qnexa, is a combination of.

Warner Chilcott to devour Proctor & Gamble drug unit

Pharmaceutical M&A is still robust. Rumors are spreading that Warner Chilcott (NASDAQ:WCRX) will purchase Proctor & Gamble’s (NYSE:PG) prescription drug unit as early as tomorrow. The price tag is rumored.

Black Cohosh, Red Clover not effective for Hot Flashes

Women who are experiencing menopausal symptoms have few treatment options. According to two studies conducted by researchers at Northwestern University and University of Illinois, two commonly used over-the-counter (OTC) remedies.

Depomed’s new Parkinson’s drug shows promise

Depomed (NASDAQ:DEPO), a specialty pharmaceutical company, reported positive updates in it’s most recent 10Q regarding it’s phase 1 clinical trial for the treatment of Parkinson’s disease with DM-1992, a novel.

Metformin lowers risks of diabetes… and pancreatic cancer

Metformin, a first-line diabetes treatment, lowers the risk of pancreatic cancer by 62%. According to a study conducted by Donghui Li, Ph.D from the University of Texas M.D. Anderson Cancer.

Pharma companies looking to Women’s Health for growth

During menopause, women experience many symptoms associated with the natural change in hormone levels. Hot flashes and sexual dysfunction are the most prevalent symptoms, and if untreated can lead to.

Wyeth drug shows promise in treating hot flashes

Today, Wyeth (NYSE:WYE) announced that their compound, bazedoxifene/conjugated-estrogens, significantly reduces the severity and frequency of menopausal hot flashes. Although the use of hormones has been associated with several potentially lethal.

Merck beefing up diabetes pipeline

Merck acquires non-exclusive license for Acuform technology from Depomed Merck plans to use technology to expand it’s diabetes portfolio Signifies the extended release diabetes market is growing more competitive Pharmaceutical.

Pfizer expanding into emerging markets: Turkey

Rumors are buzzing in the pharma sector. Pfizer (NYSE:PFE) may be considering a takeover of Abdi Ibrahim, Turkey’s largest pharmaceutical company, demonstrating Pfizer’s shift from domestic markets to emerging markets..

Browsing 20 / 3 articles